Skip to main content
Premium Trial:

Request an Annual Quote

ABI President Cathy Burzik Steps Down; Applera CEO White Becomes Interim President

NEW YORK (GenomeWeb News) — Applied Biosystems President Cathy Burzik stepped down a little more than two years after being tapped to run the business after Mike Hunkapiller retired.
 
She left to take over as CEO of Kinetic, a San Antonio-based company specializing in advanced wound care and therapeutic surfaces.
 
Applera President and CEO Tony White has become interim president “partnering with the AB leadership team. ABI said the changes are effective immediately.
 
In a statement, White said ABI “has a strong management team and organizational structure and is performing well, and we expect to continue with the strategies and the team that have revitalized the business.”
 
He said he and ABI’s directors will “carefully consider our alternatives for the management succession.”
 
Burzik took over the helm of ABI after Michael Hunkapiller retired in August 2004. She joined ABI in September 2003 from Johnson & Johnson, where she was president of the company’s Ortho-Clinical Diagnostics business. Before being named president of ABI Burzik had been executive vice president and COO at ABI.
 
At Kinetic Burzik will replace Denny Ware, who had been planning to retire, Kinetic said in a statement.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.